medigraphic.com
Órgano Científico Oficial de SOCIEM-UCV

2009, Number 1

<< Back

Acta Cient Estud 2009; 7 (1)

Pénfigo Bulloso. Presentación de un caso y revisión de la literatura

Sánchez HJA, Muñoz ZG, Mendoza LE, Islas DG, Briones RR, Tapia HA

Language: Spanish
References: 25
Page: 49-56
PDF size: 188.44 Kb.


ABSTRACT

Bullous Pemphigoid [BP] is the most common autoinmune blistering disease of the skin, representing 70% of the autoimmune dermatological diseases, with a characteristic square of tense blisters in the skin. It is more common in old people but also it can affect to young people and children; the cause of BP is not clear, being associated to multiple factors, the diagnosis can be made starting from clinical findings, histological aspects and immunological technical. Its treatment consists on suppressing the clinical signs to tolerate the disease of who suffers that it, being the corticosteroids the treatment of election, particularly oral. A clinical case is presented of masculine patient with 33 years of age at the beginning of its suffering, resident of the city of Puebla (México) and investigator of microbiology in grounds, to whom clinically is diagnosed BP prescribing itself to him of alternated way oral corticosteroids that controlled the square by 5 years, due to personal reasons he decides to be assisted with homeopath who prescribes treatment during year and a half obtaining apparent remission of the disease so far current.


REFERENCES

  1. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with Bullous Pemphigoid. N Engl J Med, Vol. 346, No. 5. January 31, 2002.

  2. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Intervenciones para el Penfigoide Bulloso (Revisión Cochrane traducida). Biblioteca Cochrane Plus. Mayo del 2006; Num 1.

  3. Lawrence Chan, MD. Bullous Pemphigoid. eMedicine, September 2, 2005.

  4. Bernard P .Bullous pemphigoid. Orphanet Encyclopedia May 2006.

  5. Rzany B, Partscht K, Jung M, et al. Risk Factors for Lethal Outcome in Patiens With Bullous Pemphigoid. Arch Dermatol. Vol 138, July 2002; 903-908.

  6. Roujeau JC, Lok C, Garin SB, et al. High Risk of Death in Elderly Patiens With Extensive Bullous Pemphigoid. Arch Dermatol. Vol. 134, Apr 1998; 465-469.

  7. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. British Journal of Dermatology 2002; 147: 214-221.

  8. Bower C. Bullous pemphigoid: guide to diagnosis and treatment. Prescriber 19 June 2006.

  9. Kavak A, Parlak AH, çetinkaya R, Tüzüner. Bullous pemphigoid on an incision scar of total knee prosthesis. Indian J Dermatol 2006; 51:70-72.

  10. Öztürkan S, Ermertcan AT, Sahin MT, Tükdogan P, Inanir I, Lekili M. Bullous pemphigoid associated with prostate adenocarcinoma. Indian J Dermatol Venereol Leprol 2004;70: 39-41

  11. Stern RS. Bullous Pemphigoid Therapy - Think Globally, Act Locally. N Engl J Med, Vol. 346, No. 5. January 31, 2002.

  12. Koster J, Geerts D, Favre B, Borradori L, Sonnenberg A. Analysis of the interactions between BP180, BP230, plectin and the integrin α6β4 important for hemidesmosome assembly. Journal of Cell Science 116, 387-399, 2003.

  13. Nishizawa Y, Uematsu J, Owaribe K. HD4, a 180 kDa Bullous Pemphigoid Antigen, Is a Major Transmembrane Glycoprotein of the Hemidesmosome. J. Biochem, Vol. 113, No. 4, 493-501, 1993.

  14. Agosto GD, Latini A, Carducci M, et al. Evaluation of Recombinant Antigen-Based Assays for Diagnosis of Bullous Autoimmune Diseases. Clinical and Diagnostic Laboratory Immunology, July 2004, p. 762-765.

  15. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. The Journal of Clinical Investigation, Vol. 116, No. 5. May 2006.

  16. Nelson KC, Zhao M, Schroeder PR, et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J. Clin. Invest. 116:2892-2900, 2006.

  17. Sharma PK, Rath N, Sharma SK, Gautham RK, Kar HK. Eosinophilic leukemoid reaction in a case of bullous pemphigoid. Indian J Dermatol Venereol Leprol 2002;68:359-360.

  18. Schumann H, Baetge J, Tasanen K, et al. The Shed Ectodomain of Collagen XVII/BP180 Is Targeted by Autoantibodies in Different Blistering Skin Diseases. American Journal of Pathology. 2000;156:685-695.

  19. Goel A, Balchandran C, Shenoi SD, Pai SB. Non-bullous variant of bullous pemphigoid: Role of immunofluorescence in diagnosis. Indian J Dermatol Venereol Leprol 2003;69:294-295.

  20. Vaillant L, Bernard P, Joly P, et al. Evaluation of Clinical Criteria for Diagnosis of Bullous Pemphigoid. Arch Dermatol. Vol. 134; Sep 1998; 1075-1080.

  21. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A Systematic Review of Treatments for Bullous Pemphigoid. Arch Dermatol. Vol 138, Mar 2002; 385-389.

  22. Korman NJ. Oral and Topical Corticosteroids in Bulluos Pemphigoid. N Engl J Med, Vol. 347: 143-145, No. 2. July 11, 2002.

  23. Iranzo P, López I, Robles MT, et al. Bullous Pemphigoid Associated With Mantle Cell Lymphoma. Arch Dermatol. Vol. 140, Dec 2004.

  24. Goon ATJ, Tan SH, Khoo LSW, Tan T. Tetracycline and Nicotinamide for the Treatment of Bullous Pemphigoid: Our Experience in Singapore. Singapore Med J 2000 Vol 41(7): 327-330.

  25. Joly P, Benichou J, Lok C, et al. Prediction of Survival for Patiens with Bullous Pemphigoid. Arch Dermatol. 2005; 141:691-698.




2020     |     www.medigraphic.com